Contract manufacturer FujiFilm Diosynth Biotechnologies, which has been expanding its footprint in Holly Springs, has signed a $3 billion agreement to make treatments for Regeneron Pharmaceuticals. Under the agreement,

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations in North Carolina, has signed an agreement valued at over $3 billion to produce biologic medicines for Regeneron Pharmaceuticals.

FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.